Best GLP-1 Programs for Medicare Patients in 2026

The Medicare GLP-1 Landscape Has Changed Overnight

Before July 2026, Medicare patients had essentially zero coverage for GLP-1 weight loss medications. The options were cash-pay at retail prices ($800–$1,300/month) or compounded alternatives. The Medicare GLP-1 Bridge changes that — but it's temporary, and it doesn't work for everyone.

Ranking: Best Options for Medicare Patients

#1: Medicare GLP-1 Bridge — $50/Month

If you qualify, this is the obvious first choice. Brand-name Foundayo, Wegovy, or Zepbound KwikPen at $50/month. The price doesn't change with dose. Available July 1, 2026 through December 31, 2027.

Who it's best for: Medicare Part D enrollees with BMI ≥ 30 (or ≥ 27 with comorbidities) who can afford the $50 copay and aren't dependent on Low-Income Subsidy pricing.

The catch: The $50 doesn't count toward your Part D deductible or out-of-pocket cap. LIS benefits don't apply. And it ends December 2027.

#2: GobyMeds — $99/Month (Compounded)

For patients who don't qualify for the Bridge, or who want pricing certainty beyond 2027, GobyMeds offers the lowest all-in compounded pricing at $99/month for semaglutide. No membership fees, free shipping, LegitScript certified.

Who it's best for: Medicare patients who don't meet Bridge criteria, want long-term cost predictability, or prefer to avoid the uncertainty of a temporary government program.

#3: Sesame Care — Brand-Name from $29/Visit

Sesame Care's pay-per-visit model works well for Medicare patients who want brand-name medications but may need help navigating prescriptions and manufacturer savings programs outside the Bridge.

#4: Embody — $149 First Month (Compounded)

For patients who want more clinical support than a basic prescription service, Embody includes metabolic reporting and 1:1 guidance. The $149 first month makes it a reasonable starting point.

#5: Gala GLP-1 — $179/Month Flat (Compounded)

Flat pricing at any dose. No surprises at higher doses. Good for patients who expect to titrate to higher doses and want cost predictability.